Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 11/20 | 0.61 |
| ▸ | CES1 | P23141 | 10/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11416768 | 1.00 | CES2 (0.61) | CES2CES1CYP2C19GAAMAPT | |
| SCHEMBL1372210 | 1.00 | CES2 (0.61) | CES2CES1CYP2C19GAAMAPT | |
| SCHEMBL1369324 | 0.87 | CES2 (0.62) | CES2CES1CYP2C19GAAMAPT | |
| SCHEMBL11424490 | 0.86 | CES2 (0.54) | CES2CES1CYP2C19GAAMAPT | |
| SCHEMBL25324982 | 0.83 | CES2 (0.56) | CES2CES1CYP2C19GAAMAPT | |
| SCHEMBL9331128 | 0.83 | CES2 (0.56) | CES2CES1CYP2C19GAAMAPT | |
| SCHEMBL7681082 | 0.82 | CES2 (0.58) | CES2CES1GAAMAPTRAB9A | |
| SCHEMBL7681076 | 0.82 | CES2 (0.58) | CES2CES1GAAMAPTRAB9A | |
| Methane SCHEMBL9572458 | 0.81 | CES2 (0.54) | CES2CES1CYP2C19GAAMAPT | |
| SCHEMBL19669112 | 0.80 | TSHR (0.50) | CES2CES1CYP2C19GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110284394-A1 | Portable Electrochemical Multiphase Microreactor for Sensing Trace Chemical Vapors | The Board of Trustees of the University Illinois Office Technology (US) | 2011-11-24 | — | — | US | claimed |
| CN-108329246-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | 阵列生物制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3569594-A1 | METHOD FOR THE PREPARATION OF SUBSTITUTED PYRAZINES | Universität Graz (AT) | 2019-11-20 | — | — | EP | disclosed |
| EP-3110818-B1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180334450-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
| US-4499283-A | Process for preparing 1-substituted-6-n-propyl-8-methylimidazo[1,5-d]-as-triazin-4-(3H)-ones | AMERICAN CYANAMID COMPANY (US) | 1985-02-12 | — | — | US | disclosed |
| US-4459413-A | Process for preparing 5-imidazolyl ketones | AMERICAN CYANAMID COMPANY (US) | 1984-07-10 | — | — | US | disclosed |
| US-4395547-A | Process for preparing 1-substituted-6-n-propyl-8-methylimidazo[1,5-d]-as-triazin-4(3H)-ones | AMERICAN CYANAMID CO. (US) | 1983-07-26 | — | — | US | disclosed |
| US-RE30752-E | CHEMICAL REACTANT FOR PROTECTING AMINO OR IMINO GROUPS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-29 | — | — | US | disclosed |
| US-4010178-A | Carbonic acid esters, and the preparation thereof and their use | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-03-01 | — | — | US | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
| US-3910763-A | Method of detecting organophosphorus agents using 1-phenyl-1,2,3-butanetrione-2-oxime and cyanide indicating composition | US ARMY | 1975-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | CES2 4003/4885CES1 2085/4885CYP2C19 4174/4885 |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | CES2 2258/4885CES1 2081/4885CYP2C19 1544/4885 |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | CES2 3340/4885CES1 3543/4885CYP2C19 2556/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | CES2 2258/4885CES1 2081/4885CYP2C19 1544/4885 |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | CES2 3917/4885CES1 2889/4885CYP2C19 2775/4885 |
| US-20180334450-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | CES2 3340/4885CES1 3543/4885CYP2C19 2556/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | CES2 2258/4885CES1 2081/4885CYP2C19 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.